BioNexus Gene Lab (BGLC) CFO files Form 3 showing zero shares
Rhea-AI Filing Summary
BioNexus Gene Lab Corp executive Chong Set Fui, the company's CFO, filed an initial statement of beneficial ownership. The filing reports 0 shares of BioNexus Gene Lab Corp common stock owned directly as of 2025-06-17, with no reported purchases, sales, or derivative positions.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Chong Set Fui
Role
CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 0 shares (Direct)
Key Figures
Common stock owned: 0 shares
Holding entries: 1
Buy transactions reported: 0
+1 more
4 metrics
Common stock owned
0 shares
Directly owned common shares following the reported holding entry on 2025-06-17
Holding entries
1
Number of holding entries listed in the initial beneficial ownership report
Buy transactions reported
0
Number of purchase transactions included in the initial statement for common stock
Sell transactions reported
0
Number of sale transactions included in the initial statement for common stock
Key Terms
Common Stock, direct_or_indirect, Rule 10b5-1
3 terms
Common Stock financial
"security_title: "Common Stock" for the holding entry"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
direct_or_indirect regulatory
""direct_or_indirect": "D" indicating direct ownership type"
Rule 10b5-1 regulatory
"Footnotes may reference Rule 10b5-1 trading plans or arrangements"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does BioNexus Gene Lab Corp's (BGLC) Form 3 show for CFO Chong Set Fui?
The Form 3 shows that CFO Chong Set Fui beneficially owns 0 shares of BioNexus Gene Lab Corp common stock directly as of 2025-06-17, and there are no listed derivative securities or other equity positions in this initial ownership report.
Does the BGLC Form 3 report any recent stock purchases or sales by the CFO?
No. The filing shows no purchase or sale transactions for CFO Chong Set Fui. Transaction counts for both buys and sells are zero, and the only entry is a holding record indicating zero common shares owned following the reported date.
Are any derivative securities reported for the BioNexus Gene Lab (BGLC) CFO on this Form 3?
No derivative securities are reported. The derivative positions section is empty, and the transaction summary shows 0 derivative transactions, indicating no listed options, warrants, or similar instruments for CFO Chong Set Fui in this initial statement.
What type of ownership is reported for the BGLC CFO in this Form 3?
The ownership type for the common stock entry is coded as direct ("D"). However, the total_shares_following_transaction value is 0.0000, so the Form 3 reflects direct ownership status but no directly held BioNexus Gene Lab Corp common shares.